Company news
Cereno Scientific Ab Class B (OMXSTO:CRNO_B) news
Cereno Scientific Ab Class B news releases on 6ix. Latest, Mar 31, 2026: Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1…
Press releases & updates
Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
March 31, 2026
Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD
March 17, 2026
Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
February 4, 2026
Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases
January 14, 2026
Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026
December 12, 2025
Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
December 8, 2025
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA
November 10, 2025